NCT00137124

L-Arginine Metabolism in Essential Hypertension

Transport and Metabolism of L-arginine: Role for Endothelial Dysfunction in Essential Hypertension

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: University of Erlangen-Nürnberg Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Essential hypertension is characterized by impaired endothelial function. Data derived from normotensive subjects with a genetic predisposition to arterial hypertension suggest that endothelial dysfunction is a cause rather than a consequence of the condition. Given that, in normotensive offspring of hypertensive parents, impaired endothelium dependent vasodilation can be restored by supplementation of the nitric oxide (NO) precursor L-arginine, a defect in the L-arginine/NO pathway can be postulated. The investigators at the University of Erlangen-Nuremberg, hypothesize that impaired endothelial function in essential hypertension is associated with alterations in L-arginine metabolism and transport. This study will determine whether metabolism and transport of L-arginine are altered in patients with essential hypertension and whether these potential alterations can be targeted therapeutically.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	L-Arginine	oral administration of L-arginine for 4 weeks

Timeline

• Start date: 2006-05-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2005-08-29
• Last updated: 2012-07-10

Locations

1 site across 1 country: Germany